Drug development – Page 2

Formulation fails stability targets during scale-up preparation – CMC risk assessment and mitigation

Mitigating Risks When Formulation Fails Stability Targets During Scale-Up Preparation In pharmaceutical development, the transition from small-scale formulation to large-scale production is fraught with risk. One of the most critical…

Dissolution variability unexplained during IND/NDA filing – CMC risk assessment and mitigation

Addressing Unexplained Dissolution Variability During IND/NDA Filing: A Comprehensive Playbook Dissolution variability during the Investigational New Drug (IND) and New Drug Application (NDA) filing can lead to significant delays, regulatory…

QbD elements missing during regulatory review – how to redesign formulation strategy

Identifying Missing QbD Elements During Regulatory Review and Redesigning Formulation Strategy In the pharmaceutical sector, the absence of Quality by Design (QbD) elements during regulatory reviews can lead to significant…

Excipient incompatibility identified late during scale-up preparation – how to redesign formulation strategy

Strategies for Addressing Late-Stage Excipient Incompatibility in Formulation Development During the critical phase of scale-up preparation, pharmaceutical development teams may encounter excipient incompatibility issues, which can severely impact timelines and…

Data reproducibility concerns during inspection support – method validation strategy

Addressing Data Reproducibility Concerns During Method Validation in Pharmaceutical Inspections In the pharmaceutical manufacturing landscape, reproducibility of data is paramount, especially during inspections that evaluate compliance with regulatory standards. Data…

Method robustness questioned during early development – scientific rigor regulators expect

“`html Assessing Method Robustness Issues During Early Development to Meet Regulatory Standards In the pharmaceutical industry, the robustness of methods employed during early development, such as during drug discovery and…

Data reproducibility concerns during tech transfer preparation – risk-based methodology optimization

Optimizing Risk-Based Methodology to Address Data Reproducibility Concerns During Tech Transfer Preparation Data reproducibility concerns during tech transfer preparation can significantly impact the success of drug development, especially in phases…

Data reproducibility concerns during scale-up readiness – preventing downstream development failure

Addressing Data Reproducibility Issues in Scale-Up Readiness to Prevent Development Failures In the highly regulated pharmaceutical landscape, achieving reproducibility of data during scale-up readiness is crucial for successful drug development.…

Experimental bias identified during early development – risk-based methodology optimization

Identifying and Mitigating Experimental Bias in Early Drug Development: A Focused Investigation In the realm of pharmaceutical research and drug development, experimental bias poses a significant risk to the integrity…

Method robustness questioned during regulatory data review – preventing downstream development failure

Ensuring Method Robustness Amidst Regulatory Scrutiny to Prevent Developmental Failures As pharmaceutical companies navigate the complex landscape of drug development, they are often confronted with challenges related to method robustness,…

Statistical power insufficient during early development – inspection-ready documentation

Addressing Insufficient Statistical Power in Early Development: An Investigation Framework In pharmaceutical development, statistical power is crucial for making informed decisions, particularly during early stages such as drug discovery and…

Experimental bias identified during regulatory data review – risk-based methodology optimization

Investigation of Experimental Bias during Regulatory Data Review for Optimized Methodology In the field of pharmaceutical manufacturing and drug development, the identification of experimental bias during regulatory data reviews poses…